STOCK TITAN
  1. Home
  2. News
  3. AFMD

Affimed N.V. - AFMD STOCK NEWS

Welcome to our dedicated news page for Affimed N.V. (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed N.V..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Affimed N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Affimed N.V.'s position in the market.

News
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
Rhea-AI Summary
Affimed N.V. (Nasdaq: AFMD) announced that the World Health Organization has selected 'acimtamig' as the nonproprietary name for the Company’s investigational drug for CD30-positive Lymphomas, previously known as AFM13. Acimtamig (AFM13) is currently being evaluated in combination with AlloNK® in patients with relapsed or refractory Hodgkin Lymphoma in LuminICE-203, a phase 2 study. The therapy was granted fast track designation by the FDA, aiming to treat serious conditions and fill an unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.12%
Tags
none
-
News
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
Rhea-AI Summary
Affimed N.V. (Nasdaq: AFMD) will release its third quarter 2023 results and corporate update on November 14, 2023. The conference call will be at 8:30 a.m. EST / 14:30 CET and available via phone and webcast. A replay of the webcast will be accessible for 30 days following the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
conferences earnings
-
News
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
Rhea-AI Summary
Affimed N.V. presented a poster at the annual meeting of the Society for Immunotherapy of Cancer (SITC) showcasing the improved cytotoxicity of natural killer (NK) cells and CAR-NK cells with the addition of Affimed's innate cell engager (ICE®). The results from a collaboration with the Fraunhofer Institute for Cell Therapy and Immunology (IZI) indicate that NK cells redirected by ICE® exhibit comparable anti-tumor efficacy to CAR-NK cells. This combination offers a cost-effective and flexible manufacturing approach as no additional engineering of NK cells is required.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
clinical trial
News
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
Rhea-AI Summary
Affimed N.V. announced the positive results of its combination treatment of AFM13 with allogeneic NK cells in patients with CD30-positive lymphoma. The treatment showed a 94.4% objective response rate and a 72.2% complete response rate. The patients were heavily pretreated and refractory to their most recent line of therapy. The treatment was well tolerated and no cases of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft versus host disease were reported. Updated clinical results will be presented in an oral presentation at the American Society of Hematology (ASH) 2023 Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
clinical trial
-
News
Affimed to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Affimed N.V. will participate in two investor conferences in November 2023: Truist Securities BioPharma Symposium on November 8-9 in New York, NY, and Jefferies London Healthcare Conference on November 14-16 in London, UK. One-on-one meetings and a presentation will be held at these conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.13%
Tags
conferences
-
News
Affimed Announces Listing Transfer to Nasdaq Capital Markets
Rhea-AI Summary
Affimed receives approval to transfer listing of shares from Nasdaq Global Market to Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.09%
Tags
none
News
Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
Rhea-AI Summary
Affimed N.V. announces acceptance of abstract for poster presentation at SITC conference comparing NK cell redirected by ICE® to CAR-NK cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none
-
News
Affimed to Present at the Cantor Global Healthcare Conference 2023
Rhea-AI Summary
Affimed's CFO to participate in fireside chat at Cantor Global Healthcare Conference 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
conferences
-
News
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
Rhea-AI Summary
FDA grants fast track designation to AFM13 and AlloNK combination therapy for relapsed/refractory Hodgkin lymphoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
clinical trial
News
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
Rhea-AI Summary
Affimed N.V. CEO to present at H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
conferences
Stock AFMD logo
Affimed N.V.

Nasdaq:AFMD

AFMD Rankings

#4427 Ranked by Market Cap
#5350 Ranked by Stock Gains
N/A Ranked by Dividends

AFMD Stock Data

81.77M
13.50M
6.01%
35.86%
1.29%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Mannheim

About AFMD

affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli